The alteration of ribosomal targets by recently described 16S rRNA methyltransferases confers resistance to most aminoglycosides, including arbekacin. Enterobacteriaceae and nonfermentative bacilli acquired through global surveillance programs were screened for the presence of these enzymes on the basis of phenotypes that were resistant to nine tested aminoglycosides. Subsequent molecular studies determined that 20 of 21 (95.2%) methyltransferase-positive isolates consisted of novel species records or geographic occurrences (North America [armA and rmtB], Latin America [rmtD], and Europe [armA]; rmtA, rmtC, and npmA were not detected). The global emergence of high-level aminoglycoside resistance has become a rapidly changing event requiring careful monitoring.
Aminoglycosides continue to play an important role in antimicrobial therapy against both gram-negative and gram-positive pathogens, usually in combination with ␤-lactam agents. Resistance to the class can be widespread and has primarily been the result of aminoglycoside inactivation through the chemical processes of acetylation, phosphorylation, and/or adenylation, with varying effects depending upon the particular agent (14) . Since 2003, methylation of 16S rRNA has emerged as a serious threat to the class through the action of plasmidmediated methyltransferase enzymes (6, (9) (10) (11) 17) . These enzymes, which are similar to those found in actinomycetes, confer intrinsic resistance to the aminoglycoside agents they produce (6, 13, 15) .
Alteration of the 16S rRNA A site by these enzymes (designated ArmA, RmtA, RmtB, RmtC, RmtD, and NpmA) confers resistance to almost all aminoglycosides, including arbekacin, by limiting the binding of these agents to ribosomal target sites following methylation of specific nucleotides. armA (Enterobacteriaceae, Acinetobacter spp.) and rmtB (Enterobacteriaceae) appear to be the most widespread and have been detected primarily in Asia and Europe (1, 2, 9, 12, 17, 18, 20) ; armA has also been reported from a clone of Acinetobacter baumannii found in the United States (Pennsylvania) (5) . rmtA and rmtC have been reported only from Japan (Pseudomonas aeruginosa and Proteus mirabilis, respectively) and rmtD from Brazil (P. aeruginosa) (7, 8, 15, 18, 19) . A sixth plasmid-mediated methyltransferase enzyme, NpmA, was recently obtained from a strain of Escherichia coli recovered from a Japanese patient (16) . NpmA is unique in that it produces a broad resistance phenotype to aminoglycosides including apramycin and neomycin, due to methylation of the A1408 position at the A site of 16S rRNA; all other methyltransferases described to date from clinical isolates methylate the G1405 position. The high level of resistance produced by these methyltransferases and their association with mobile genetic elements have become a worrisome development that will require enhanced laboratory capabilities for detection, appropriate infection control practices to limit continued spread, and when detected, reliance on alternative chemotherapeutic agents (6, 10, 11, 17) .
While the occurrence of 16S methylation by these gene products appears to be widespread globally, structured prevalence data are urgently needed. We evaluated Enterobacteriaceae family members and nonfermentative bacilli acquired through global surveillance programs for the presence of methyltransferases, based upon patterns of resistance to commonly used aminoglycosides.
Enterobacteriaceae (262 isolates), P. aeruginosa (95 isolates) and Acinetobacter spp. (50 isolates) were selected from recent surveillance collections (from North America, Latin America, and Europe) on the basis of their resistance to combinations of gentamicin, tobramycin, and amikacin and were tested further for susceptibility using the Clinical Laboratory Standards Institute (CLSI) broth microdilution methods against six other aminoglycosides (apramycin, arbekacin, fortimicin, kanamycin, neomycin, and netilmicin) (3, 4) . High-level resistance to all aminoglycosides in the panel, except for apramycin and neomycin, has been described as the defining phenotype characteristic for ArmA, RmtA, RmtB, RmtC, and RmtD methyltransferase resistance mechanisms; additionally, resistance to apramycin and neomycin appears to be typical for the NpmA mechanism (6, 16) . Strains were selected for further study based on the MIC results from this aminoglycoside screen.
Primers for diagnostic amplification of the armA, rmtA to rmtD, and npmA genes were designed from sequences deposited in the GenBank database or were selected from the literature (Table 1) (15, 19) . Primers were designed to have similar annealing temperatures for simultaneous amplification on a single thermocycler program. Templates for PCRs were prepared by suspending a single colony in 100 l of sterile water. Suspensions were heated to 95°C for 10 min, cooled to room temperature, and centrifuged to pellet the cell debris. The addition of 2 l of the template supernatant to reaction mixtures containing the appropriate primer sets was used to initiate reactions.
Amplification was performed in an Eppendorf Mastercycler (Eppendorf, Westbury, NY). The PCR method consisted of 25 cycles of denaturation at 94°C for 15 s, annealing at 58°C (45°C for those isolates found to be PCR negative at 58°C) for 30 s, and extension at 72°C for 60 s. This was followed by an additional 10-min extension at 72°C. The entire reaction mixture was loaded onto an E-Gel (Invitrogen, Carlsbad, CA) for rapid gel electrophoresis. Visualization of bands by UV light confirmed the presence of the target methylase gene. A plasmid containing the armA gene (kindly provided by Patrice Courvalin) was used as a positive control for the presence of armA in the collection of clinical isolates. Upon our initial identification of rmtB and rmtD, these PCR products were submitted for DNA sequencing to confirm their identity by comparison to previously reported sequences. These confirmed strains were subsequently employed as positive controls for further screening.
Susceptibility profiling of 407 gram-negative isolates resistant to combinations of gentamicin, tobramycin, and amikacin in the initial screen revealed 19 strains that were subsequently found to be resistant to all 4,6-di-substituted aminoglycosides (Table 2) . Two additional strains were selected on the basis of apramycin susceptibility and neomycin resistance, since aph(3Ј)-I is a widespread resistance gene that reduces the potency of neomycin (14) . A final strain chosen for further study displayed high-level resistance to all aminoglycosides tested (including apramycin and neomycin) and was found to be positive for aph(3Ј)-I and aac(3)-IV enzymes (data not shown).
Among the 22 isolates selected for further analysis, 21 (5.2% of the initial screen total) isolates were confirmed to carry methyltransferase genes (9 isolates carried armA, 8 carried rmtB, and 4 carried rmtD; A methyltransferase gene could not be identified in one isolate (Chile [P. mirabilis]) that met the aminoglycoside resistance screening criteria, suggesting the presence of an additional variant enzyme or some other resistance mechanism, and is being investigated further (16) . No methyltransferases were found in this collection among the P. aeruginosa or Acinetobacter sp. isolates, although an earlier pilot study identified 
baumannii).
The extraordinary level of aminoglycoside resistance produced by methyltransferases and the association of their genes with mobile elements are troubling developments that will require enhanced laboratory capabilities for detection, appropriate infection control practices to limit continued spread, and when detected, reliance on alternative chemotherapeutic agents. Aminoglycosides continue to play a critical role in therapeutics, often for their synergistic codrug effects when paired with agents from other classes. Adjustments of existing treatment algorithms and the development of new aminoglycoside agents that bind to methylated ribosomes are critically needed to help address this latest example of emerging antimicrobial resistance. (5) France (1); United States (1) Mexico (1) Chile (1); Argentina (1) K. oxytoca (1) Poland (1) P. mirabilis (3) Brazil (2) Chile (1) Serratia marcescens (3) Poland (3) Citrobacter freundii (1) Brazil (1) VOL. 52, 2008 NOTES 1845
